Hospitals & Providers

The new global DNA registry could help enable more precise treatments and identify who’s at risk for certain health problems.

A new study shows efforts to reduce prescription opioid use in adults has not curtailed the incidence of pediatric opioid ingestions. Find out why.

Reduce readmissions by focusing on better engagement with patients and improving coordination from inpatient to outpatient settings.

Rideshare giants Uber and Lyft partner with providers to help get patients to their medical appointments, as well as improve the overall patient experience. Here’s five takeaways from industry watchers.

The Cigna-Express Scripts deal may signal a move to more vertical and horizontal healthcare deals. Here’s what else it means.

HHS Secretary Alex M. Azar II lays out top four HHS initiatives and calls on payers and providers to align.

This first article in our new leadership series explores how managed care executives can cultivate smart ideas and stay ahead of the competition.

Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.

Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.

Eye-opening research by NTT DATA Services sheds light on healthcare consumer satisfaction with virtual versus human agents.

Hospitals are always looking for ways to reduce readmission rates. They may have an unusual ally in a quality control system originally developed in Europe for the manufacturing sector. Read more about it.

A study from Human Rights Watch has eye-opening findings about antipsychotic drug prescribing in U.S. nursing homes.

Managed care organizations are looking for new skills in healthcare leaders (and in some cases hiring for completely new leadership roles). Here are four emerging trends to watch.

Anthem’s decision has sparked criticism and concern, but could it reduce healthcare spending? Experts weigh in.

John R. Washlick, Buchanan, Ingersoll & Rooney, and expert in healthcare system transactions and market consolidation, talks to Managed Healthcare Executive about healthcare spin-offs, what that means for the future of mergers and acquisitions, and advice for healthcare executives.

A new report reveals the top cities that rise to the top for healthcare-and they’re probably not the cities you’d expect.

The healthcare landscape is transforming. Here are six considerations to help your talent during restructuring, downsizing, and other transitions.

Make the rules work for, rather than, against you by relying on these five critical capabilities.

Here are three strategies to navigate toward next-generation care management and increase member engagement in the process

Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.

Putting together the right team of data specialists is an important part of the future growth of a healthcare organization. Do you have the right team in place?

Health systems realize that telehealth can help them achieve a wide range of objectives, from care coordination to readmission avoidance and market share expansion.

Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.

Corporate giants Amazon, Berkshire Hathaway, and JPMorgan Chase, partner to shake things up in U.S. employee healthcare.

Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.

A Stanford expert describes ideal treatment locations, common barriers, and how payers could better support patients and families.

The flu epidemic is taking a toll on the U.S. healthcare system. Here's how health insurers can curtail spending on flu care.

From State-led programs to innovative pharmacist-hospital partnerships, these programs are fighting to quell the epidemic.

How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.

Many providers are overlooking important steps that can help guide proper COPD treatment and therefore, reduce admissions and readmissions.